Skip to main content

Advertisement

SpringerLink
Log in

Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches

  • Review
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Objectives: Renal cell carcinoma is an aggressive malignancy with a high propensity for both early and metachronous regional and distant metastasis. While surgical resection is the mainstay of therapy for patients with localized disease, the prognosis for patients with distant metastasis is poor with a 5-year survival rate of less than 10%. Response rates to first-line immunotherapy or immunochemotherapy range from 10–35%; responses achieved are predominantly partial remissions of short duration. Until today, there is no standard therapeutic procedure for the growing number of patients who relapse following first-line therapy and desire further active treatment. Materials and Methods: This article reviews classic and recent publications about second- and third-line approaches, their potential efficacy and toxicity. Results: Several novel approaches have raised well-founded hope. Especially the application of monoclonal antibodies targeting VEGF signalling as well as different receptor tyrosine kinase inhibitors have the potential to change the face of second-line treatment of patients with metastatic RCC. Both groups of agents are focused in current phase III trials, either as mono- and/or combination therapy. Conclusions: Until today, second-line treatment of patients with metastatic RCC progressing under therapy with biological response modifiers remains an unresolved issue. The results of ongoing clinical trials evaluating novel targeted approaches can be expected with suspense.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK (2003) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011–1021

    PubMed  CAS  Google Scholar 

  • Adlard JW (2000) Thalidomide in the treatment of cancer. Anticancer Drugs 11:787–791

    Article  PubMed  CAS  Google Scholar 

  • Ahmad T, Eisen T (2004) Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10:6388S–6392S

    Article  PubMed  CAS  Google Scholar 

  • Amato RJ (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 27:177–186

    PubMed  CAS  Google Scholar 

  • Amato RJ (2003) Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol 46:S59–S65

    PubMed  Google Scholar 

  • Amato RJ (2005) Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16:7–15

    Article  PubMed  CAS  Google Scholar 

  • Amato RJ, Schell J, Thompson N, Moore R, Miles B (2003) Phase II study of thalidomide + interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC) (abstr 1556). Proc Am Soc Clin Oncol 22:387

    Google Scholar 

  • Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909–918

    Article  PubMed  CAS  Google Scholar 

  • Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H, Fornara P, Loening SA, Roigas J, Muller SC, Bodenstein H, Pomer S, Metzner B, Rebmann U, Oberneder R, Siebels M, Wandert T, Puchberger T, Reitz M (2004) Interleukin-2- and interferon Alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German cooperative renal carcinoma chemoimmunotherapy Group (DGCIN). J Clin Oncol 22:1188–1194

    Article  PubMed  CAS  Google Scholar 

  • Bai R, Pettit GR, Hamel E (1990) Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39:1941–1949

    Article  PubMed  CAS  Google Scholar 

  • Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E (2002) Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 13:1259–1263

    Article  PubMed  CAS  Google Scholar 

  • Berg WJ, Schwartz LH, Amsterdam A, Mazumdar M, Vlamis V, Law TM, Nanus DM, Motzer RJ (1997) A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs 15:353–355

    Article  PubMed  CAS  Google Scholar 

  • Blaise D, Bay JO, Faucher C, Michallet M, Boiron JM, Choufi B, Cahn JY, Gratecos N, Sotto JJ, Francois S, Fleury J, Mohty M, Chabannon C, Bilger K, Gravis G, Viret F, Braud AC, Bardou VJ, Maraninchi D, Viens P (2004) Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 103:435–441

    Article  PubMed  CAS  Google Scholar 

  • Bleiberg H, de Gramont A (1998) Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 25:32–39

    PubMed  CAS  Google Scholar 

  • Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, De Mulder P, Mulders PF, Beck J (2004) A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90:985–990

    Article  PubMed  CAS  Google Scholar 

  • Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319–323

    PubMed  CAS  Google Scholar 

  • Brandes AA, Pasetto LM, Vastola F, Monfardini S (2000) Temozolomide in patients with high grade gliomas. Oncology 59:181–186

    Article  PubMed  CAS  Google Scholar 

  • Buer J, Probst M, Duensing S, Koditz H, Franzke A, Dallmann I, Ganser A, Atzpodien J (1997) Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma. Cancer Biother Radiopharm 12:143–147

    Article  PubMed  CAS  Google Scholar 

  • Bukowski RM (2003) AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert Opin Investig Drugs 12:1403–1411

    Article  PubMed  CAS  Google Scholar 

  • Cameron RB, McIntosh JK, Rosenberg SA (1988) Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res 48:5810–5817

    PubMed  CAS  Google Scholar 

  • Chaouche M, Pasturaud AL, Kamioner D, Grandjean M, Franiatte J, Tourani JM (2000) Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma: results of a pilot study. Am J Clin Oncol 23:288–289

    PubMed  CAS  Google Scholar 

  • Chauffert B, Bonnette B, Chvetzoff G, Flesh M (1998) Réponse majeure d’un cancer du rein métastatique à l’association oxaliplatine, 5-fluorouracile et acide folinique. Nouv Press Med 27:859

    CAS  Google Scholar 

  • Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (2000) Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750–758

    Article  PubMed  CAS  Google Scholar 

  • Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L (2003) VEGF-receptor signal transduction. Trends Biochem Sci 28:488–494

    Article  PubMed  CAS  Google Scholar 

  • D’Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082–5

    PubMed  CAS  Google Scholar 

  • Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM (2002) A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95:1629–1636

    Article  PubMed  CAS  Google Scholar 

  • Elias L, Sandoval JM (1989) Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun 163:867–874

    Article  PubMed  CAS  Google Scholar 

  • Escudier B, Chevreau C, Lasset C, Douillard JY, Ravaud A, Fabbro M, Caty A, Rossi JF, Viens P, Bergerat JP, Savary J, Negrier S (1999) Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? J Clin Oncol 17:2039–2043

    PubMed  CAS  Google Scholar 

  • Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A (2002) Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 13:1029–1035

    Article  PubMed  CAS  Google Scholar 

  • Escudier B, Venner P, Bukowski R, Szczylik C, Oudard S, Champagne P, Hariton C, Dupont E (2003) Phase III study of neovastat in metastatic renal cell carcinoma patients refractory to immunotherapy. Eur J Cancer 1(Suppl):329

    Google Scholar 

  • Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, Bukowski RM (2005) Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (abstr LBA4510). J Clin Oncol 23:380s

    Google Scholar 

  • Famoyin C, Byrnes C, Roberts S, Gollob J, Atkins M, Mier J, Ko YJ, Gautam S, McDemott D (2004) A randomized phase II study of thalidomide with or without erythropoietin (EPO) in metastatic renal cell carcinoma (RCC). J Clin Oncol 22:4747

    Google Scholar 

  • Fossa SD, Martinelli G, Otto U, Schneider G, Wander H, Oberling F, Bauer HW, Achtnicht U, Holdener EE (1992) Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 3:301–305

    PubMed  CAS  Google Scholar 

  • Friedland D, Leon L, Manola J, Dutcher JP, Roth B, Wilding G (2002) Carboxyamidotriazole (CAI) in patients with advanced renal cell cancer (RCC) refractory to immunotherapy: an ECOG phase II trial. ASCO Annual Meeting abstract 2424

  • Friedman HS, Kerby T, Calvert H (2000) Temozolomide and treatment of malignant glioma. Clin Cancer Res 6:2585–2597

    PubMed  CAS  Google Scholar 

  • George D, Michaelson D, Oh WK, Reitsma D, Laurent D, Mietlowski W, Wang Y, Dugan M, Kaelin WG, Kantoff P (2003) Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma (abstr 1548). Proc Am Soc Clin Oncol 22:385

    Google Scholar 

  • Gil-Delgado MA, Antoine EC, Guinet F, Bassot V, Grapin JP, Benhammonda A, Adam R, Castaing D, Bismuth H, Khayat D (2001) Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer. Am J Clin Oncol 24:251–254

    Article  PubMed  CAS  Google Scholar 

  • Hainsworth JD, Sosman JA, Spigel DR, Schwert RC, Carrell DL, Hubbard F, Greco FA (2004) Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). J Clin Oncol 22:4502

    Google Scholar 

  • Hainsworth JD, Sosman JA, Spigel DR, Patton JF, Thompson DS, Sutton V, Hart LL, Yost K, Greco FA (2005) Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: a minnie pearl cancer research network phase I/II trial (abstr 4542). J Clin Oncol 23:388s

    Google Scholar 

  • Hartmann JT, Bokemeyer C (1999) Chemotherapy for renal cell carcinoma. Anticancer Res 19:1541–1543

    PubMed  CAS  Google Scholar 

  • Heidenreich A, Schrader AJ, Varga Z (2003) Basic science and research in renal cell carcinoma: from workbench to bedside. Curr Opin Urol 13:457–462

    Article  PubMed  Google Scholar 

  • Heidenreich A, Haupt G, Ohlmann CH, Engelmann UH (2005) Temozolomide in the management of progressive metastatic renal cell cancer (RCC) following immunotherapy (abstract). Eur Urol 4:916

    Google Scholar 

  • Hernberg M, Virkkunen P, Bono P, Ahtinen H, Maenpaa H, Joensuu H (2003) Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 21:3770–3776

    Article  PubMed  CAS  Google Scholar 

  • Huang S, Houghton PJ (2003) Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3:371–377

    Article  PubMed  CAS  Google Scholar 

  • Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA (1996) Negative regulation of hypoxia-inducible genes by the von Hippel–Lindau protein. Proc Natl Acad Sci USA 93:10595–10599

    Article  PubMed  CAS  Google Scholar 

  • Jac J, Hernandez J, Phan S, Amato RJ (2005) Phase II trial of motexafin gadolinium (MGd) for treatment of metastatic renal cell carcinoma (MRCC) (abstr 4724). J Clin Oncol 23:433s

    Google Scholar 

  • Kalemkerian GP, Ou X, Adil MR, Rosati R, Khoulani MM, Madan SK, Pettit GR (1999) Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol 43:507–515

    Article  PubMed  CAS  Google Scholar 

  • Kedar I, Mermershtain W, Ivgi H (2004) Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int J Cancer 110:260–265

    Article  PubMed  CAS  Google Scholar 

  • Kirkali Z, Oebek C (2003) Clinical aspects of renal cell carcinoma. EAU Update Series 1:189–196

    Article  Google Scholar 

  • Kirkali Z, Tuzel E, Mungan MU (2001) Recent advances in kidney cancer and metastatic disease. BJU Int 88:818–824

    Article  PubMed  CAS  Google Scholar 

  • Kish JA, Wolf M, Crawford ED, Leimert JT, Bueschen A, Neefe JR, Flanigan RC (1994) Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer 74:916–919

    PubMed  CAS  Google Scholar 

  • Lam JS, Leppert JT, Belldegrun AS, Figlin RA (2005) Novel approaches in the therapy of metastatic renal cell carcinoma Epub 2005 Apr 5. World J Urol 23:202–212

    Article  PubMed  CAS  Google Scholar 

  • Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O’Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF (1995) Phase III randomized trial of interleukin-2 with or without lymphokine–activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76:824–832

    PubMed  CAS  Google Scholar 

  • Lissoni P, Barni S, Ardizzoia A, Crispino S, Paolorossi F, Archili C, Vaghi M, Tancini G (1992) Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer 28:92–96

    Article  PubMed  CAS  Google Scholar 

  • Lopez Hanninen E, Fenner M, Kirchner H, Deckert M, Duensing S, Menzel T, Poliwoda H, Atzpodien J (1993) Limited efficacy of interferon-alpha and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinoma. Cancer Biother 8:301–306

    PubMed  CAS  Google Scholar 

  • Lyons JF, Wilhelm S, Hibner B, Bollag G (2001) Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8:219–225

    Article  PubMed  CAS  Google Scholar 

  • Maisey NR, Hall K, Lee C, Timotheadou E, Ahern R, Eisen T, Gore M (2004) Infliximab: A phase II trial of the tumour necrosis factor (TNFa) monoclonal antibody in patients with advanced renal cell cancer (RCC). J Clin Oncol 22:4514

    Article  PubMed  CAS  Google Scholar 

  • Massenkeil G, Roigas J, Nagy M, Wille A, Stroszczynski C, Mapara MY, Loening S, Dorken B, Arnold R (2004) Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 34:309–316

    Article  PubMed  CAS  Google Scholar 

  • Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–275

    Article  PubMed  CAS  Google Scholar 

  • Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166

    PubMed  CAS  Google Scholar 

  • Miki T, Nonomura N, Takaha N, Nishimura K, Kojima Y, Sawada M, Okuyama A (1998) Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice. Int J Urol 5:370–373

    PubMed  CAS  Google Scholar 

  • Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368–1375

    PubMed  CAS  Google Scholar 

  • Minor DR, Amato RJ (2004) Thalidomide, interferon-alpha, and capecitabine as second-line therapy for metastatic renal cell cancer (RCC). J Clin Oncol 22:4696

    Google Scholar 

  • Morgan M, Rawat A, Amato RJ (2005) Phase II study of thalidomide, interleukin-2 (IL-2), and granulocyte macrophage-colony stimulating factor (GM-CSF) in patients (pts) with metastatic renal cell carcinoma (MRCC) (abstr 4717). J Clin Oncol 23:432s

    Article  Google Scholar 

  • Morgensztern D, McLeod HL (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16:797–803

    Article  PubMed  CAS  Google Scholar 

  • Morita T, Tokue A (1999) Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase. Cancer Chemother Pharmacol 44:91–96

    Article  PubMed  CAS  Google Scholar 

  • Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408–417

    Article  PubMed  CAS  Google Scholar 

  • Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004a) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463

    Article  Google Scholar 

  • Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Zhu J, Kim ST, Baum C (2004b) SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: results of a phase 2 trial. J Clin Oncol 22:4500

    Article  Google Scholar 

  • Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Bukowski RM, Georget DJ, Kim ST, Baum CM (2005) Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) (abstr 4508). J Clin Oncol 23:380s

    Google Scholar 

  • Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP (1997) The von Hippel–Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17:5629–5639

    PubMed  CAS  Google Scholar 

  • Nathan PD, Gore ME, Eisen TG (2002) Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol 20:1429–1430

    PubMed  CAS  Google Scholar 

  • O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605

    Article  PubMed  CAS  Google Scholar 

  • Pagliaro LC, Perez CA, Tu SM, Daliani DD (2003) Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma (abstr 1780). Proc Am Soc Clin Oncol 22:443

    Google Scholar 

  • Pantuck AJ, Zisman A, Belldegrun AS (2001) The changing natural history of renal cell carcinoma. J Urol 166:1611–1623

    Article  PubMed  CAS  Google Scholar 

  • Paolorossi F, Villa S, Barni S, Tancini G, Andres M, Lissoni P (1995) Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy. Tumori 81:45–47

    PubMed  CAS  Google Scholar 

  • Park DK, Ryan CW, Dolan ME, Vogelzang NJ, Stadler WM (2002) A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol 50:160–162

    Article  PubMed  CAS  Google Scholar 

  • Pfeffer LM, Tamm I (1984) Interferon inhibition of thymidine incorporation into DNA through effects on thymidine transport and uptake. J Cell Physiol 121:431–436

    Article  PubMed  CAS  Google Scholar 

  • Pitot HC, Frytak S, Croghan GA, Hillman DW, Reid JM, Ames M, Richardson RL, Moynihan TJ, Windebank AJ, Burch PA (2002) Phase II study of dolastatin-10 (dola-10) in patients (pts) with advanced renal cell carcinoma. ASCO Annual Meeting abstract 2409

  • Ratain MJ, Flaherty KT, Stadler WM, O’Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T (2004) Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol 22:4501

    Article  Google Scholar 

  • Ravaud A, Trufflandier N, Ferriere JM, Debled M, Palussiere J, Cany L, Gaston R, Mathoulin-Pelissier S, Bui BN (2003) Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial. Br J Cancer 89:2213–2218

    Article  PubMed  CAS  Google Scholar 

  • Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23:1028–1043

    Article  PubMed  CAS  Google Scholar 

  • Rini BI, Vogelzang NJ, Dumas MC, Wade JL 3rd, Taber DA, Stadler WM (2000) Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18:2419–2426

    PubMed  CAS  Google Scholar 

  • Rini BI, Zimmerman T, Stadler WM, Gajewski TF, Vogelzang NJ (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 20:2017–2024

    Article  PubMed  Google Scholar 

  • Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, Bolte O, Steinfeldt H, Reich SD, Motzer R (2005) AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). In: ASCO annual meeting abstract 4509

  • Roigas J, Massenkeil G (2005) Nonmyeloablative allogeneic stem cell transplantation in metastatic renal cell carcinoma: a new therapeutic option or just a clinical experiment? World J Urol 23:213–220

    Article  PubMed  Google Scholar 

  • Saad ED, Kraut EH, Hoff PM, Moore DF Jr, Jones D, Pazdur R, Abbruzzese JL (2002) Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Am J Clin Oncol 25:451–453

    Article  PubMed  Google Scholar 

  • Schilsky RL. (1992) Antimetabolites. In: Perry M (ed) The chemotherapy sourcebook. William and Wilkins, Philadelphia, pp 301–317

    Google Scholar 

  • Schmidinger M, Steger GG, Budinsky AC, Wenzel C, Brodowicz T, Locker GJ, Kramer G, Marberger M, Zielinski CC (2000) Vinorelbine and interferon-alpha2c as second-line therapy in metastatic renal cell carcinoma. Anticancer Drugs 11:175–179

    Article  PubMed  CAS  Google Scholar 

  • Schrader AJ, von Knobloch R, Heidenreich A, Buer J, Hofmann R (2004) Application of retinoids in the treatment of renal cell carcinoma-a futile effort? Anticancer Drugs 15:819–824

    Article  PubMed  CAS  Google Scholar 

  • Schrader AJ, Heidenreich A, Hegele A, Olbert P, Ohlmann CH, Varga Z, von Knobloch R, Hofmann R (2005) Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma. Anticancer Drugs 16:581–585

    Article  PubMed  CAS  Google Scholar 

  • Shamash J, Steele JP, Wilson P, Nystrom M, Ansell W, Oliver RT (2003) IPM chemotherapy in cytokine refractory renal cell cancer. Br J Cancer 88:1516–1521

    Article  PubMed  CAS  Google Scholar 

  • Spigel DR, Hainsworth JD, Sosman JA, Raefsky EL, Meluch AA, Edwards D, Horowitz P, Thomas K, Yost K, Stagg MP, Greco FA (2005) Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma: update of a phase II multicenter trial (abstr 4540). J Clin Oncol 23:387s

    Google Scholar 

  • Stadler WM, Halabi S, Ernstoff MS, Barrier R, Davila E, Picus J, Small EJ (2004) A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): a report of cancer and leukemia group B #90008. J Clin Oncol 22:4515

    Google Scholar 

  • Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff CA, Sinibaldi V, Carducci MA (2004) A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma. J Interferon Cytokine Res 24:37–41

    Article  PubMed  CAS  Google Scholar 

  • Tannir NM, Jonasch E, McMichael C, Wang X, Wooten L, Ng CS (2005) A phase II trial of gemcitabine plus capecitabine (GX) in patients with advanced renal cell cancer (mRCC) previously treated with immunotherapy (abstr 4598). J Clin Oncol 23:402s

    Google Scholar 

  • Tykodi SS, Warren EH, Thompson JA, Riddell SR, Childs RW, Otterud BE, Leppert MF, Storb R, Sandmaier BM (2004) Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 10:7799–7811

    Article  PubMed  CAS  Google Scholar 

  • Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE (2003) Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102:3829–3836

    Article  PubMed  CAS  Google Scholar 

  • Wadler S, Wersto R, Weinberg V, Thompson D, Schwartz EL (1990) Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res 50:5735–5739

    PubMed  CAS  Google Scholar 

  • Waters JS, Moss C, Hackett S, James M, Pyle L, A’Hern R, Gore M, Eisen T (2003) A phase II trial of gemcitabine (GEM) plus capecitabine (CAPE) in patients with metastatic renal cell carcinoma (MRCC) (abstr 1549). Proc Am Soc Clin Oncol 22:386

    Google Scholar 

  • Wenzel C, Locker GJ, Bartsch R, Pluschnig U, Mader R, Hussian D, Kramer G, Marberger M, Lintner C, Rauchenwald M, Zielinski CC, Steger GG (2003) Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. Anticancer Drugs 14:779–784

    Article  PubMed  CAS  Google Scholar 

  • Whelan P (2003) The medical treatment of metastatic renal cell carcinoma. EAU Update Ser 1:237–246

    Article  Google Scholar 

  • Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 22:42–60

    PubMed  CAS  Google Scholar 

  • Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003a) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434

    Article  CAS  Google Scholar 

  • Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA (2003b) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127–3132

    Article  CAS  Google Scholar 

  • Zhuang SH, Menefee M, Kotz H, Agrawal M, Poruchynsky M, Hung E, Zhan Z, Linehan WM, Bates SE, Fojo T (2004) A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. J Clin Oncol 22:4550

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Philipps-University Medical School, Baldingerstrasse, 35043, Marburg, Germany

    A. J. Schrader, Z. Varga, A. Hegele, P. Olbert & R. Hofmann

  2. Department of Cell Biology and Immunology, German Research Centre for Biotechnology, Mascheroder Weg 1, 38124, Braunschweig, Germany

    A. J. Schrader & S. Pfoertner

Authors
  1. A. J. Schrader
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Z. Varga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Hegele
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Pfoertner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Olbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. J. Schrader.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schrader, A.J., Varga, Z., Hegele, A. et al. Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol 132, 137–149 (2006). https://doi.org/10.1007/s00432-005-0058-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-005-0058-4

Keywords

Search

Navigation